Peculiarities of immunopathogenesis of interstitial cystitis/syndrome of a pained bladder

Abstract

The aim of the study was to determine the expression of cytokines, mast cells quantity in the bladder mucosa and their relationship in patients with IC/BPS.

Material and methods. A total of 126 women with clinically diagnosed IC/BPS were examined, mean age 46.7 ± 14.0 years. The concentration of interleukins (IL)-1β, IL-6, IL-8, tumor necrosis factor a (TNFα) in blood serum was determined by ELISA. Mast cells were identified in biopsy specimens of the bladder mucosa taken during cystoscopy using histological analysis.

Statistical analysis was performed using the Statistica program in Microsoft Excel release 6 (StatSoft, USA). The Pearson correlation coefficient is calculated.

Result. In the main group, moderate pain was observed in 56.3 % of cases, and urination more than 8 times a day in 59.5 % of cases. The average level of pro-inflammatory cytokines -IL-1β, IL-6, IL-8 and TNFα in the blood serum of the examined main group was higher than in the comparison group by 63.34, 66.67, 68.83 and 70.16 % respectively. The number of mast cells averaged 82.27 ± 38.76. Mast cells number correlated with IL-6 and IL-8 weak, with TNFa - a noticeable relationship (r = -0,418). There was a moderate negative correlation between the mast cells number and the level of TNFα (r = -0.418), no significant correlation with the levels of IL-6 and IL-8 was found.

Conclusion. The identification of cytokines in patients with IC/BPS can be used to improve the diagnosis and exclusion criteria for this pathology. Analysis of serum cytokines and mast cells is a convenient approach to monitoring the activation of inflammatory cells in the tissue of the bladder.

Keywords:interstitial cystitis/bladder pain syndrome; cytokines; mast cells; biopsy; correlation

For citation: Sholan R.F. Peculiarities of immunopathogenesis of interstitial cystitis/syndrome of a pained bladder. Immunologiya. 2019; 41 (3): 274-9. DOI: 10.33029/0206-4952-2020-41-3-274-279 (in Russian)

Funding. The study had no sponsor support.

Conflict of interests. The author declare no conflict of interests.

References

1. Keller J.J., Chen Y.K., Lin H.C. Comorbidities of bladder pain syndrome/interstitial cystitis: a population-based study. BJU Int. 2012; 110 (11 Pt C): E9039. DOI: 10.1111/j.1464-410X.2012.11539.x.

2. Slesarevskaya M.N., Ignashov Yu.A., Kuz’min I.V. Modern approaches to the diagnosis of painful bladder syndrome. Urologicheskie vedomosti. 2017; 7 (2): 25–3. DOI: 10.17816/uroved7225-30. (in Russian)

3. Ke Q.-S., Kuo H.-C. Pathophysiology of interstitial cystitis/bladder pain syndrome. Tzu Chi Med. J. 2015; 27 (4): 139–44. URL: https://doi.org/10.1016/j.tcmj.2015.09.006.

4. Duh K., Funaro M.G., DeGouveia W., Bahlani S., Pappas D., Najjar S., et al. Crosstalk between the immune system and neural pathways in interstitial cystitis/bladder pain syndrome. Discov. Med. 2018; 25 (139): 243–50.

5. Wang L., Wang F.S., Gershwin M.E. Human autoimmune diseases: a comprehensive update. J. Intern. Med. 2015; 278 (4): 369–95. DOI: 10.1111/joim.12395.

6. Akiyama Y., Morikawa T., Maeda D., Shintani Y., Niimi A., Nomiya A., et al. Increased CXCR3 expression of infiltrating plasma cells in Hunner type interstitial cystitis. Sci. Rep. 2016; 24 (6): 28652. URL:http://dx.doi.org/10.1038/srep28652.

7. Grover S., Srivastava A., Lee R., Tewari A.K., Te A.E. Role of inflammation in bladder function and interstitial cystitis. Ther. Adv. Urol. 2011; 3 (1): 19–33. URL: http://dx.doi.org/10.1177/1756287211398255.

8. Shaik-Dasthagirisaheb Y.B., Varvara G., Murmura G., Saggini A., Potalivo G., Caraffa A., et al. Vascular endothelial growth factor (VEGF), mast cells and inflammation. Int. J. Immunopathol. Pharmacol. 2013; 26 (2): 327–35. DOI: 10.1177/039463201302600206.

9. Jiang Y.-H., Peng C.-H., Liu H.-T., Kuo H.-C. Increased pro-inflammatory cytokines, C-reactive protein and nerve growth factor expressions in serum of patients with interstitial cystitis/bladder pain syndrome. PLoS One. 2013; 8 (10): e76779. DOI: 10.1371/journal.pone.0076779.

10. Peters K.M., Diokno A.C., Steinert B.W. Preliminary study on urinary cytokine levels in interstitial cystitis: does intravesical Bacille Calmette-Guerin treat interstitial cystitis by altering the immune profile in the bladder? Urology. 1999; 54 (3): 450–3.

11. Peng C.H., Jhang J.F., Shie J.H., Kuo H.C. Down regulation of vascular endothelial growth factor is associated with decreased inflammation after intravesical Onabotulinum toxin A injections combined with hydrodistention for patients with interstitial cystitis – clinical results and immunohistochemistry analysis. Urology. 2013; 82 (6): 1452.e1–6. DOI: 10.1016/j.urology.2013.09.003.

12. Smaldone M.C., Vodovotz Y., Tyagi V., Barclay D., Philips B.J., Yoshimura N., et al. Multiplex analysis of urinary cytokine levels in rat model of cyclophosphamide-induced cystitis. Urology. 2009; 73 (2): 421–6. DOI: 10.1016/j.urology.2008.07.031.

13. World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013; 310 (20): 2191–4.

14. Gillenwater J.Y., Wein A.J. Summary of the National Institute of Arthritis, Diabetes and Kidney Diseases. Workshop on Interstitial Cystitis. National Institutes of Health, Bethesda, Maryland, August 28-29, 1987. J. Urol. 1988; 140: 203–6. DOI: 10.1016/S0022-5347(17)41529-1.

15. Bayrak O., Seckiner I., Solakhan M., Karakok M., Erturhan S.M., Yagci F. Effects of intravesical dexpanthenol use on lipid peroxidation and bladder histology in a chemical cystitis animal model. Urology. 2012; 79: 1023–6. DOI: 10.1016/j.urology.2012.01.025.

16. Corcoran A.T., Yoshimura N., Tyagi V., Jacobs B., Leng W., Tyagi P. Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens. World J. Urol. 2012; 31 (1): 2416. DOI: 10.1007/s00345-012-0852-y.

17. Mirkin Ya.B., Karapetyan A.V. Interstitial cystitis: pathogenesis, diagnosis and treatment (part 2). Eksperimental’naya i klinicheskaya urologiya. 2018; 2: 118–22. (in Russian)

18. Mishra N.N. Clinical presentation and treatment of bladder pain syndrome/interstitial cystitis (BPS/IC) in India. Transl. Androl. Urol. 2015; 4 (5): 512–23. DOI: 10.3978/j.issn.2223-4683.2015.10.05.

19. Jhang J.-F., Kuo H.-C. Pathomechanism of interstitial cystitis/bladder pain syndrome and mapping the heterogeneity of disease. Int. Neurourol. J. 2016; 20 (2): S95–104. DOI: 10.5213/inj.1632712.356.

20. Liu H.T., Kuo H.C. Biomarkers for patients with interstitial cystitis/bladder pain syndrome. Urol. Sci. 2015; 26: 225–9. URL: https://doi.org/10.1016/j.urols.2015.02.002.

21. Gamper M., Viereck V., Eberhard J., Binder J., Moll C., Welter J., Moser R. Local immune response in bladder pain syndrome/interstitial cystitis ESSIC type 3C. Int. Urogynecol. J. 2013; 24 (12): 2049–57. DOI: 10.1007/s00192-013-2112-0.

22. Lamale L.M., Lutgendorf S.K., Zimmerman M.B., Kreder K.J. Interleukin-6, histamine, and methylhistamine as diagnostic markers for interstitial cystitis. Urology. 2006; 68 (4): 702–6. URL: https://doi.org/10.1016/j.urology.2006.04.033.

23. Gonzalez E.J., Arms L., Vizzard M.A. The role(s) of cytokines/chemokines in urinary bladder inflammation and dysfunction. Biomed. Res. Int. 2014; 2014: 120525. DOI: 10.1155/2014/120525.

24. Ogawa T., Homma T., Igawa Y., Seki S., Ishizuka O., Imamura T., et al. CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis. J. Urol. 2010; 183 (3): 1206–12. DOI: 10.1016/j.juro.2009.11.007.

25. Ratner V. The importance of mast cells in interstitial cystitis/bladder pain syndrome. Transl. Androl. Urol. 2016; 5 (3): 398. DOI: 10.21037/tau.2016.03.19.

26. Haidl I.D., Marshall J.S. Human mast cell activation with viruses and pathogen products. Methods Mol. Biol. 2015; 1220: 179–201. URL: http://dx.doi.org/10.1007/978-1-4939-1568-2_12.

27. Aldenborg F., Fall M., Enerbäck L. Proliferation and transepithelial migration of mucosal mast cells in interstitial cystitis. Immunology. 1986; 58 (3): 411–6.

28. Cardamone C., Parente R., Feo G.D., Triggiani M. Mast cells as effector cells of innate immunity and regulators of adaptive immunity.Immunol. Lett. 2016; 178: 10–4. DOI: 10.1016/j.imlet.2016.07.003.

29. Gamper M., Regauer S., Welter J., Eberhard J., Viereck V. Are mast cells still good biomarkers for bladder pain syndrome/interstitial cystitis? J. Urol. 2015; 193 (6): 1994–2000. DOI: 10.1016/j.juro.2015.01.036.

30. Akiyama Y., Maeda D., Morikawa T., Niimi A., Nomiya A., Yamada Y., et al. Digital quantitative analysis of mast cell infiltration in interstitial cystitis. Neurourol. Urodyn. 2018; 37 (2): 650–7. URL: https://doi.org/10.1002/nau.23365.

CHIEF EDITOR
CHIEF EDITOR
Rakhim M. Khaitov
Аcademician of the Russian Academy of Sciences, MD, Professor, Honoured Science Worker of the Russian Federation, Scientific Director of the NRC Institute of Immunology FMBA of Russia, Chief Allergist-Immunologist of the Ministry of Health of the Russian Federation

Medicine today

Московская урологическая школа Урология - область медицинской науки, которая интенсивно развивается. Ежегодно появляются новые научные данные, обнародуются результаты исследований и разработок, меняются алгоритмы диагностики и лечения пациентов с теми или иными болезнями...

24-25 ноября 2020 г. состоится Юбилейная научно-практическая конференция с международным участием "120 лет кафедре оториноларингологии с клиникой ПСПбГМУ им. акад. И.П. Павлова". Мероприятие, посвященное 120-летию со дня основания второй в России кафедры, пройдет в...

Всероссийская научно-практическая конференция "Левитановские чтения" - 2020 27-28 ноября 2020 г. состоится Всероссийская научно-практическая конференция "Левитановские чтения", посвященная различным аспектам организации медицинской помощи пациентам с язвенным колитом и...


JOURNALS of «GEOTAR-Media»